Effects of Oral Vitamin B1 and Mecobalamin on Dry Eye Disease
Table 2
Comparison of pre- and posttreatment in each group.
Group 1
Group 2
Group 3
Group 4
B
1
2
B
1
2
B
1
2
B
1
2
Signs (mean ± SD)
TMH (mm)
0.18 ± 0.05
0.20 ± 0.07
0.21 ± 0.07
0.16 ± 0.06
0.18 ± 0.07
0.17 ± 0.07
0.18 ± 0.05
0.17 ± 0.06
0.18 ± 0.07
0.17 ± 0.05
0.19 ± 0.06
0.18 ± 0.07
TBUTF (s)
5.19 ± 2.65
5.23 ± 2.20
5.85 ± 2.60
4.70 ± 1.80
4.87 ± 2.37
6.12 ± 3.81
4.21 ± 1.21
4.89 ± 1.80
5.31 ± 2.07#
3.98 ± 1.80
4.55 ± 1.62
5.10 ± 2.74
TBUTA (s)
6.60 ± 2.85
7.06 ± 2.15
7.55 ± 3.28
5.93 ± 1.79
6.15 ± 2.15
7.55 ± 3.28∂#
5.70 ± 1.71
6.46 ± 1.48
6.44 ± 2.33
5.09 ± 1.97
5.95 ± 1.95
6.71 ± 2.78
CNFD (mm/mm2)
14.14 ± 2.84
16.56 ± 1.76
17.51 ± 1.05
13.47 ± 1.14
13.33 ± 1.93
14.36 ± 1.61
6.54 ± 1.85
9.71 ± 2.49
13.93 ± 2.59#
7.11 ± 2.48
10.55 ± 2.12
15.98 ± 1.72#
Symptoms (mean ± SD, scores)
Dryness
5.13 ± 3.41
6.03 ± 3.03
5.83 ± 3.61
6.15 ± 3.14
5.58 ± 2.92
5.70 ± 2.79
6.15 ± 3.07
6.43 ± 3.54
4.69 ± 3.30∂#
5.88 ± 3.13
4.47 ± 3.32
4.64 ± 3.03
Foreign body sensation
3.70 ± 3.70
4.88 ± 3.47
4.88 ± 3.40
3.38 ± 3.61
3.30 ± 3.07
3.98 ± 3.36
5.38 ± 3.64
5.30 ± 3.43
3.42 ± 3.41∂#
4.66 ± 3.76
3.47 ± 3.79
3.59 ± 3.57
Pain
1.95 ± 3.00
1.50 ± 2.61
2.00 ± 2.88
2.65 ± 3.18
2.75 ± 2.97
2.83 ± 3.03
3.63 ± 3.18
2.80 ± 3.30
2.04 ± 2.86
4.03 ± 3.61
2.53 ± 3.29
3.82 ± 3.57
Burning
1.15 ± 1.86
1.65 ± 2.77
1.45 ± 2.73
2.25 ± 3.18
2.40 ± 2.99
2.93 ± 2.74
2.10 ± 3.18
2.33 ± 3.34
0.96 ± 1.97#
2.47 ± 3.65
1.44 ± 2.33
1.27 ± 2.90
Watering
2.10 ± 2.92
2.50 ± 3.10
2.48 ± 3.03
2.30 ± 3.04
2.28 ± 3.04
2.33 ± 2.78
4.05 ± 3.59
3.33 ± 3.87
3.73 ± 3.54
1.94 ± 3.15
2.16 ± 3.33
2.00 ± 3.27
Asthenopia
4.50 ± 3.80
5.30 ± 3.07
5.10 ± 3.39
5.75 ± 3.46
6.23 ± 2.95
5.75 ± 3.20
5.65 ± 3.22
6.00 ± 3.22
4.96 ± 3.37
4.31 ± 3.76
3.97 ± 3.34
5.23 ± 3.19∂
Blurred vision
3.55 ± 3.56
2.20 ± 3.12
3.60 ± 3.51#
3.10 ± 3.62
3.45 ± 3.04
3.20 ± 3.43
3.13 ± 3.49
2.85 ± 3.42
3.81 ± 3.37
3.97 ± 4.04
2.81 ± 3.41
3.41 ± 3.59
Itching
2.85 ± 2.89
2.60 ± 2.47
3.15 ± 2.98
2.15 ± 3.45
2.25 ± 3.10
3.48 ± 3.23
2.98 ± 3.33
3.23 ± 3.18
2.58 ± 3.20
2.59 ± 3.26
1.88 ± 2.65
1.91 ± 2.86
Increased secretions
1.25 ± 2.81
1.05 ± 2.63
1.23 ± 1.82
1.35 ± 2.72
2.48 ± 3.45
2.20 ± 2.59
2.43 ± 3.61
2.48 ± 3.22
3.27 ± 2.99
3.66 ± 3.53
3.28 ± 3.74
2.73 ± 3.38
Photophobia
3.40 ± 3.82
3.95 ± 3.74
3.33 ± 3.59
4.80 ± 3.69
4.90 ± 3.64
4.03 ± 3.29
5.00 ± 3.82
4.63 ± 3.93
3.54 ± 3.39#
4.84 ± 3.90
3.75 ± 3.67
3.68 ± 3.71
Total
29.58 ± 17.97
31.33 ± 14.67
32.95 ± 19.70
33.88 ± 12.88
35.60 ± 17.47
36.40 ± 15.38
40.48 ± 21.45
39.35 ± 20.73
32.73 ± 23.33
38.34 ± 23.67
29.75 ± 23.07
32.27 ± 25.31
Satisfaction (mean ± SD, scores)
Before
4.00 ± 2.63
3.60 ± 2.99
3.82 ± 2.60
4.50 ± 2.40
4.22 ± 2.50
4.20 ± 2.56
4.41 ± 2.97
3.40 ± 2.19
2.82 ± 1.30
3.29 ± 2.59
3.60 ± 2.17
3.50 ± 3.13
After
5.21 ± 2.62
5.72 ± 2.21
5.67 ± 2.32
6.05 ± 2.14
5.87 ± 2.62
6.27 ± 2.10
4.67 ± 1.67
5.31 ± 3.03
After-before
1.43 ± 2.39
1.89 ± 1.97
1.44 ± 1.92
1.85 ± 1.39
2.47 ± 2.65
3.45 ± 2.24∂
0.50 ± 1.77
2.00 ± 2.18
Following advice
9.07 ± 2.33
8.94 ± 2.18
8.83 ± 1.44
8.50 ± 1.55
9.53 ± 1.28
9.55 ± 0.80
9.86 ± 0.36
9.29 ± 1.20
Improvement
6.00 ± 3.11
5.56 ± 3.16
6.28 ± 3.19
6.80 ± 2.89
6.33 ± 2.77
7.36 ± 2.32
6.57 ± 2.34
5.86 ± 3.90
B: baseline; 1: 1 month; 2: 2 months; TMH: tear meniscus height; TBUTF: tear film breakup time first; TBUTA: tear film breakup time average; CNFD: corneal nerve fiber density. Satisfaction: before: pretreatment satisfaction with ocular surface; after: posttreatment satisfaction with ocular surface; following advice: compliance with the doctor's advice; improvement: satisfaction with therapeutic effects. values of less than 0.05 were considered statistically significant and are expressed as 1 month versus baseline, #2 months versus baseline, and ∂2 months versus 1 month in the same group.
